died of disease, and one from infection. Clinical staging, avoiding splenectomy, reduced the risk of serious infections. Our current policy is to treat stage IA disease with local irradiation and all other stages with chemotherapy, adding irradiation for bulky mediastinal disease.
Children with Hodgkin's disease have an excellent prognosis with the prospect of long disease free survival in approximately 80%. . Staging techniques and treatment protocols that are used in adults, however, have been associated with significant morbidity-anit even mortality. Extended field irradiation which includes bony epiphyses compromises growth and frequently results in musculoskeletal deformity.2 3 5 Combination chemotherapy containing mustine causes distressing nausea and vomiting and leads to infertility in adult males6 and also in boys treated before or during puberty.7 8 Splenectomy in children with Hodgkin's disease is hazardous with the risk of fulminant septicaemia in up to 10%.7 9 In addition there is an increased risk of a second primary malignancy in such children, especially those treated with a combination of extensive irradiation and chemotherapy. 7 This report describes a new protocol, begun in September 1974, designed to avoid splenectomy and reduce irradiation fields and doses. Chemotherapy was given for both early and advanced disease, using ChlVPP (chlorambucil, vinblastine, procarbazine and prednisolone),10 a combination causing much less nausea and vomiting than mustine-containing combinations. 1 
Patients and methods
From September 1974 to August 1982, 80 newly diagnosed children were staged and treated for Hodgkin's disease, and follow up continued to September 1983. Histology was classified by the Rye system.'2 There were 56 boys and 24 girls (ratio 2-3:1) whose median age was 10*6 years, (range 2-8 to 15 9 years).
Staging included physical examination, haematology profile, plasma liver function tests, and chest radiograph. Lymphography (with intravenous urogram) was undertaken provided there was no respiratory impairment. Lung tomography, computed tomography, ultrasound, and isotope scans were performed when indicated. Bone marrow trephine was undertaken on 72 children, and laparotomy was necessary for diagnosis in one child. In the first four years of the study, staging laparotomies were performed in 18 children before treatment-on completing therapy in six, at relapse in two, and for other indications in one boy who did not have a splenectomy. Staging laparotomy included sampling of iliac, para-aortic, mesenteric, periportal, and splenic hilar lymph nodes; splenectomy; wedge biopsy of liver; and bone marrow trephine. Staging, by the Ann Arbor convention,'3 was pathological in 19 children underging laparotomy before treatment, and clinical in the remainder. After splenectomy, prophylactic penicillin or erythromycin was given until at least 20 years of age.
Treatment
Treatment followed the Children's Solid Tumour Group protocol, which was modified during the first three years as laparotomy was phased out. LD=lymphocyte depletion. of courses to achieve complete remission. Those who did not remit after five courses were changed to alternative chemotherapy. Five of seven stage IV children with bulky mediastinal disease or pulmonary infiltration, or both, received irradiation to these sites after chemotherapy. All radiotherapy was administered using a 6 or 8 MeV linear accelerator. Fifty five children were treated with chemotherapy followed by radiotherapy, 13 with chemotherapy alone, and 12 with radiotherapy alone. There were some deviations from the protocol in the first few years. Six children with pathological stage I and one with pathological stage II and small volume disease were treated with extended field irradiation, and two with pathological stage III disease with total nodal irradiation, to 35 and 40 Gy respectively. Four children (age less than 7 years) received additional courses of chemotherapy because radiotherapy fields would have included extensive growing bone.
Complete remission was defined as resolution of all abnormal symptoms, signs, and investigations attributable to Hodgkin's disease. Actuarial overall and relapse free survival rates were computed from diagnosis by standard Kaplan-Meier methods, and differences between curves by the log rank test.
Clinical presentation. Lymphadenopathy was a presenting symptom in 72 children (90%) with enlargement of cervical or supraclavicular nodes in 51 (63%). Constitutional symptoms of fever, sweats, or loss of more than 10% of body weight were noted in 17 (21%). Thirteen (16%) had splenomegaly, 7 (8%) hepatomegaly, and 17 (21%) were anaemic (haemoglobin less than 10 g/dl). None presented with superior vena caval obstruction. In eight diagnosis had been delayed by an earlier lymph node biopsy which had not shown Hodgkin's disease.
Histology and staging. Nodular sclerosis predominated in both girls (75%) and boys (54%) ( Table 2 ). The male predominance (2.3:1) and the incidence of nodular sclerosis in boys were both greater than in an earlier study from the Royal Marsden Hospital.1
Diesease stage distribution is shown in Table 2 . Pathological staging upstaged six children and confirmed clinical staging in the remaining 13. Laparotomy showed that the spleen was affected in 10, which in seven had not been detected clinically. One child with splenomegaly had a histologically normal spleen, but had clinical stage III disease with' abdominal node involvement on lymphography (confirmed on biopsy). Although six children changed stage after laparotomy, different treatment was indicated in only three. One, upstaged from clinical stage IIA to pathological stage IIIA because Chemotherapy is now so effective that we expect it to reclaim any relapses.
All other patients are treated with ChlVPP chemotherapy, with addition of low dose irradiation only for bulky mediastinal disease. New approaches are still needed for the small minority who fail with current treatment, and efforts must continue to develop even less toxic treatments, particularly those with no risk of carcinogenesis, the major potential long term problem in this approach to treatment.
